Portola Pharma (PTLA) Tops Q3 EPS by 54c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 7, 2018 4:05 PM ESTThird Quarter Andexxa Product Revenues of $7.7 Million
Company Improves Financial Expectations for 2018 Operating Expenses
Conference Call Today at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2018 and provided a corporate update.
I am excited to join Portola at such a pivotal moment in the Companys history. Having just completed my first month in role, I am very encouraged by the... More
